Drugs / CAP-232
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00422786 | Mar 2007 → Mar 2008 | renal cell carcinoma | Thallion Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAP-232 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00422786 ↗ |
| Route | Intravenous | “CAP-232 via continuous IV infusion” NCT00422786 ↗ |